Efficacy of Intrapleural or Intrapericardial Injection of Single Bevacizumab in the Treatment of Lung Cancer-Mediated Malignant Effusion

The usage of bevacizumab for malignant pleural effusion (MPE) or malignant pericardial effusion (MPCE) has attracted increasing interest from researchers, but the precise ways of bevacizumab administration remain unknown. Patients with histologically or cytologically confirmed non-small-cell lung cancer (NSCLC) with MPE or MPCE were enrolled in the study and treated with a low dose of single bevacizumab (100 mg) intrapleurally or intrapericardially injected after the drainage of the effusions. The Lung Cancer Symptom Scale (LCSS), efficacy, and safety of drug administration were used as evaluation parameters in this study. The results indicated that lung cancer-related symptoms were significantly improved following treatment, compared with symptoms before the treatment (LCSS, score 494 ± 78 vs. score 377 ± 77, mean ± SD) (P < 0.001). Malignant effusions were well controlled, and the median time to progression (TTP) was 91 days and 111 days in MPE and MPCE, respectively. In addition, no severe side effects were observed, except in one patient with mild dizziness. In summary, the low dose of single bevacizumab (100 mg) with intrapleural or intrapericardial injection is effective and safe in the treatment of lung cancer-mediated malignant effusion, rapidly improving the malignant effusion-related symptoms and quality of life in patients with NSCLC.

[1]  Youxin Ji,et al.  A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of malignant pleural effusion in patients with non‐small‐cell lung cancer , 2019, Thoracic cancer.

[2]  Shuhang Wang,et al.  Comparative study of EGFR mutations detected in malignant pleural effusion, plasma and tumor tissue in patients with adenocarcinoma of the lung. , 2019, Lung cancer.

[3]  K. Kaira,et al.  Intrapericardial carboplatin in the management of malignant pericardial effusion in breast cancer: a pilot study , 2019, Cancer Chemotherapy and Pharmacology.

[4]  Yujie Liu,et al.  贝伐珠单抗治疗非小细胞肺癌所致恶性胸腔积液的研究进展 , 2019, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[5]  H. Chen,et al.  Comparative study of EGFR mutations detected in malignant pleural effusion, plasma and tumor tissue in patients with adenocarcinoma of the lung. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  R. Sarpong,et al.  Bio-inspired synthesis of xishacorenes A, B, and C, and a new congener from fuscol† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c9sc02572c , 2019, Chemical science.

[7]  Yao Chen,et al.  The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non-small cell lung cancer , 2018, Molecular medicine reports.

[8]  Zhang Yan,et al.  Evaluation of efficacy and safety for bevacizumab in treating malignant pleural effusions caused by lung cancer through intrapleural injection , 2017, Oncotarget.

[9]  Y. C. Lee,et al.  Effect of an Indwelling Pleural Catheter vs Talc Pleurodesis on Hospitalization Days in Patients With Malignant Pleural Effusion: The AMPLE Randomized Clinical Trial , 2017, JAMA.

[10]  Rong Biaoxue,et al.  Thoracic perfusion of recombinant human endostatin (Endostar) combined with chemotherapeutic agents versus chemotherapeutic agents alone for treating malignant pleural effusions: a systematic evaluation and meta-analysis , 2016, BMC Cancer.

[11]  Hidekazu Suzuki,et al.  Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion. , 2016, Anticancer research.

[12]  Peng Li,et al.  Effective Treatment for Malignant Pleural Effusion and Ascites with Combined Therapy of Bevacizumab and Cisplatin. , 2016, Anticancer research.

[13]  Shuanying Yang,et al.  Matrine promotes the efficacy and safety of platinum-based doublet chemotherapy for advanced non-small cell lung cancer. , 2015, International journal of clinical and experimental medicine.

[14]  J. M. Porcel,et al.  Clinical features and survival of lung cancer patients with pleural effusions , 2015, Respirology.

[15]  Xiaosong Li,et al.  Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion. , 2013, Oncology reports.

[16]  A. Mansfield,et al.  The Role of Vascular Endothelial Growth Factor in the Pathogenesis, Diagnosis and Treatment of Malignant Pleural Effusion , 2013, Current Oncology Reports.

[17]  J. Subramanian,et al.  Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  B. Liang,et al.  Transcription expression and clinical significance of vascular endothelial growth factor mRNA and endostatin mRNA in pleural effusions of patients with lung cancer , 2012, Diagnostic cytopathology.

[19]  Edmund Neville,et al.  Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010 , 2010, Thorax.

[20]  C. Bokemeyer,et al.  Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? , 2009, The oncologist.

[21]  F. Marte,et al.  Pericardial effusion with elevated serum carbohydrate antigen 125 levels and ovarian tumor mass. , 2008, International journal of cardiology.

[22]  S. Ramalingam,et al.  Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. , 2008, The oncologist.

[23]  M. Barnes,et al.  The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. , 2006, Gynecologic oncology.

[24]  F. Emmrich,et al.  Vascular endothelial growth factor in pleural effusions of different origin , 2005, European Respiratory Journal.

[25]  J. Matute,et al.  [Parapneumonic effussion. A review of 33 cases over 6 years]. , 2005, Cirugia pediatrica : organo oficial de la Sociedad Espanola de Cirugia Pediatrica.

[26]  L. Ellis,et al.  Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis. , 2001, International journal of oncology.

[27]  R. Light,et al.  Vascular endothelial growth factor in pleural fluid. , 1999, Chest.

[28]  M. Kris,et al.  Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the lung cancer symptom scale , 1994, Cancer.

[29]  M. Kris,et al.  Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS). , 1993, European journal of cancer.